Literature DB >> 9728562

Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination.

D M Granoff1, R K Gupta, R B Belshe, E L Anderson.   

Abstract

Thirty-four adults were vaccinated with 1/50 of the usual dose of meningococcal polysaccharide vaccine (1 microg of A, C, Y, and W135 polysaccharides, given intramuscularly). This dose was selected as a probe to assess B cell memory. The probe elicited meningococcal C bactericidal antibody responses in all 18 adults who had been vaccinated 4 years earlier with an investigational meningococcal A and C oligosaccharide-protein conjugate vaccine and in the majority of the 11 subjects vaccinated for the first time. In contrast, the responses of the 5 adults given a full dose of licensed polysaccharide vaccine 4 years earlier were <1/10 of those of the other 2 groups. Thus, adults previously given a full dose of meningococcal polysaccharide vaccine show evidence of immunologic refractoriness to group C polysaccharide, whereas refractoriness is not observed after conjugate vaccination. These findings have implications for the use of meningococcal polysaccharide vaccine when the risk of disease is low.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9728562     DOI: 10.1086/515346

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  42 in total

1.  Meningococcal group C conjugate vaccines.

Authors:  J Maclennan
Journal:  Arch Dis Child       Date:  2001-05       Impact factor: 3.791

Review 2.  Mucosal immunology of vaccines against pathogenic nasopharyngeal bacteria.

Authors:  Q Zhang; A Finn
Journal:  J Clin Pathol       Date:  2004-10       Impact factor: 3.411

Review 3.  The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine.

Authors:  Robert Welte; Caroline L Trotter; W John Edmunds; Maarten J Postma; Philippe Beutels
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 4.  Anti-pneumococcal antibody titre measurement: what useful information does it yield?

Authors:  Paul Balmer; Andrew J Cant; Ray Borrow
Journal:  J Clin Pathol       Date:  2006-09-01       Impact factor: 3.411

5.  Importance of complement source in measuring meningococcal bactericidal titers.

Authors:  G F Santos; R R Deck; J Donnelly; W Blackwelder; D M Granoff
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

Review 6.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

Review 7.  Regulation of capsule in Neisseria meningitidis.

Authors:  Yih-Ling Tzeng; Jennifer Thomas; David S Stephens
Journal:  Crit Rev Microbiol       Date:  2015-06-19       Impact factor: 7.624

Review 8.  Vaccine-preventable infections in Systemic Lupus Erythematosus.

Authors:  Giuseppe Murdaca; Andrea Orsi; Francesca Spanò; Valeria Faccio; Francesco Puppo; Paolo Durando; Giancarlo Icardi; Filippo Ansaldi
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

Review 9.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

10.  Purified capsular polysaccharide of Neisseria meningitidis serogroup A as immune potentiator for antibody production.

Authors:  Tamara Menéndez; Tania Carmenate; Yoelys Cruz-Leal; Edelgis Coizeau; Evelyn Caballero; Daniel Bello; María Guirola; Anabel Alvarez; Gerardo Guillén
Journal:  Curr Microbiol       Date:  2009-09-23       Impact factor: 2.188

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.